We reported cash, cash equivalents and marketable securities of $252.2 million as of December 31, 2023. Combined with gross proceeds of approximately $100 million from our recent PIPE financing, and based on our revised pipeline priorities, we now expect our current cash, cash equivalents and marketable securities to fund planned operations into at least the second half of 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTYX:
- Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event
- Ventyx Biosciences to hold virtual investor event
- Ventyx Biosciences Secures $100M in Private Placement Deal
- Ventyx Biosciences to sell 11.17M shares at $8.95 in private placement
- Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
